Likely in breast cancer, bone morphogenetic protein 6 (BMP6) competitively binds to the miR-21 promoter through the E2-box- and AP-1-binding sites, leading to inhibition of the expression of miR-21 and enhancing E-cadherin to achieve EMT inhibition [102]. Here, BMP6 is linked to breast cancer.